Istanbul—An experimental immunity-enhancing drug administered as a topical gel shows promise in substantially delaying onset of recurrent genital herpes lesions, researchers reported here at the 11th European Congress of Clinical Microbiology and Infectious Diseases.
"One episodic treatment seems to act like a vaccination and prolong the time to the next recurrence," explained Spotswood Spruance, MD, at a symposium sponsored by St Paul, Minn–based 3M Pharmaceuticals. If the findings are confirmed in large-scale studies, the new agent, resiquimod, would provide an alternative to current suppressive therapy for genital herpes, said Spruance, of the University of Utah School of Medicine in Salt Lake City.
Stephenson J. New Therapy Promising for Genital Herpes. JAMA. 2001;285(17):2182-2183. doi:10.1001/jama.285.17.2182-JMN0502-2-1